30 results
Thumbnail

D2.332 - Patients With HAE Report Positive Perceptions Following Berotralstat Treatment: Results from a Focus Group

Thumbnail

D2.325 - Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study

Thumbnail

D2.326 - Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study

Thumbnail

D2.327 - Outcome of hematopoietic stem cells transplantation for inborn error of immunity in Vietnam

Thumbnail

D2.328 - Comparison of the frequency of viral infections in immunocompromised patients receiving immunoglobulin by different routes

Thumbnail

D2.329 - Impact of Berotralstat on Quality of Life among Patients with Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials

Thumbnail

D2.330 - Hereditary angioedema prophylaxis therapy: berotralstat and lanadelumab safety profile

Thumbnail

D2.331 - Lanadelumab safety and efficacy in patients aged ≥12 with hereditary angioedema (HAE) in China for long-term prophylaxis (LTP): An open-label, multicenter study

Thumbnail

D2.334 - Real-World Effectiveness of Lanadelumab in Hereditary Angioedema: A 12-Month Retrospective Study at a Single Center in Colombia

Thumbnail

D2.336 - Evolution of Hereditary Angioedema Prophylaxis in Hungary Over Four Decades (1979-2023)

Thumbnail

D2.338 - The Effect of Covid-19 Vaccines on Adult Primary Immunodeficiency Patients

Thumbnail

D2.339 - Hereditary Angioedema Burden: Impact on Quality of Life, Disease Management, and Sleep Health

Thumbnail

D2.340 - A high prevalence of autoimmune diseases and autoantibodies in patients with hereditary angioedema in Sweden

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes

Thumbnail

D3.416 - Hereditary Alpha-Tryptasemia: A Case Series